The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic bone marrow or peripheral blood stem cell transplantation at Veterans General Hospital, Kaohsiung from February 1997. In 12 consecutive patients receiving allogeneic bone marrow or peripheral blood stem cell transplantation, ciprofloxacin-resistant Escherichia coli bacteremia developed in three (25%). In addition to our data, increasing evidence suggests that the widespread use of a fluoroquinolone is associated with the emergence of resistant isolates as well as documented infections caused by these resistant strains. The incidence of Escherichia coli bacteremia in our transplant patients was 25%, which was similar to that in patients not receiving preventive therapy or in those receiving trimethoprim-sulfamethoxazole prophylaxis. The prophylactic efficacy of ciprofloxacin in allogeneic bone marrow transplant or peripheral blood stem cell transplant recipients should therefore be reassessed.
Bacterial infection remains one of the main causes of mortality and morbidity in patients receiving BMT or peripheral blood stem cell transplants (PBSCT) despite early aggressive antimicrobial therapy. 1 Prophylaxis for bacterial infection during the neutropenic phase using prophylactic antibiotics was therefore introduced. Although the 'optimal' antimicrobial prophylactic regimen for BMT or PBSCT recipients remains to be elucidated, fluoroquinolone, because of its high antimicrobial activity against gram-negative organisms, high bioavailibility and high tolerability, becomes one of the most attractive candidates in this regard. The efficacy of fluoroquinolone has been well documented and it can virtually eliminate bacteremia caused by gram-negative organisms.
2- 6 Ciprofloxacin has therefore been incorporated into the antimicrobial prophylactic regimen for allogeneic BMT and PBSCT at Veterans General Hospital-Kaohsiung since February 1997. Unfortunately, ciprofloxacin-resistant Escherichia coli (E. coli) bacteremia was encountered relatively frequently. Among 12 consecutive patients receiving allogeneic BMT and PBSCT, ciprofloxacin-resistant E. coli bacteremia developed in three, and two died, accounting for the entire transplant-related mortality in our patients. Although cases of fluoroquinolone-resistant E. coli infections have been increasingly reported, 7, 8 fluoroquinolone-resistant E. coli bacteremia in BMT recipients has never been reported systemically to date. We therefore report our experience. The concern about emergence of drug resistance as well as the efficacy of fluoroquinolone prophylaxis during BMT will be discussed.
Patients and methods

Patients
Twelve consecutive patients undergoing allogeneic BMT or PBSCT between February 1997 and November 1998 at the Veterans General Hospital-Kaohsiung, a 1100-bed medical center with a specialized hematology-oncology service and a two-bed bone marrow transplantation unit, were included in this study. Patients eligible for BMT or PBSCT were those with AML in first CR, high risk ALL in first CR, ALL in second or subsequent CR, CML in chronic phase, and severe aplastic anemia (SAA). Patient characteristics are shown in Table 1 . Apart from case No. 11 who received PBSCT, all the other patients received BMT. The donors were HLA-matched siblings except in case No. 6 and No. 7 who received BMT from an HLA-matched unrelated donor and two-locus mismatched sibling donor, respectively. A double-lumen Hickman catheter was inserted 1 week before treatment started. All patients were nursed in a single room with high efficiency particulate air (HEPA) filtration. All persons who entered the room were required to wash hands and wear a sterile gown, cap, mask and gloves. All food and other items entering the transplant unit were sterilized. This protective isolation was maintained until myeloid engraftment (defined as an absolute neutrophil count Ͼ1 ϫ 10 9 /l). All patients received G-CSF D12 = day 12 from BMT; M5 = 5 months after BMT; CNS = coagulase-negative staphylococci; PTLD = post-transplantation lymphoproliferative disorder; ATG = anti-thymocyte globulin; CR-E. coli = ciprofloxacin-resistant E. coli; ch. phase = chronic phase. 300 g i.v. daily from day 2 (date of BMT or PBSCT was 'day 0') until myeloid engraftment and all patients received standard GVHD prophylaxis with cyclosporin A and shortcourse methotrexate.
Antimicrobial prophylaxis and clinical evaluation
All patients received oral ciprofloxacin 250 mg twice daily, fluconazole 100 mg once daily and penicillin 1 MU i.v. every 6 h from day Ϫ5 to myeloid engraftment or the first episode of fever (defined as an axillary temperature of 38°C or more). Cotrimoxazole (sulfamethoxazole/trimethoprim: 400 mg/80 mg), two tablets, was given orally twice daily from day Ϫ5 to day Ϫ2 and twice weekly from myeloid engraftment to day 180 or the whole duration on immunosuppressive agents. Because all patients were cytomegalovirus seropositive, acyclovir 250 mg/m 2 i.v. every 8 h was also given from day Ϫ1 to myeloid engraftment. Patients were examined daily for symptoms and signs of infection. Each episode of fever was investigated by repeating cultures of blood obtained via the Hickman catheter and peripheral vein, urine, sputum, feces and any clinically suspicious secretions. After the first episode of fever, the initial prophylactic antibiotics were discontinued except for fluconazole, and ceftazidime or piperacillin plus an aminoglycoside were given as empirical treatment. If fever persisted for more than 72 h, fluconazole was substituted with full dose amphotericin B. Vancomycin was added only when catheter-related infection was suspected clinically or a resistant gram-positive organism was isolated.
Results
The prophylactic antibiotics were tolerated well and no patient interrupted the regimen before the onset of fever. Only two of a total of 12 patients remained free of fever and infection during the neutropenic phase after transplantation. Of the other 10 patients, nine had their first episode of fever before day 10 and only one patient (case No. 10) developed fever on day 12. The majority of febrile episodes remained unexplained despite repeated microbiological cultures. However, four patients had documented bacteremias. The causative organisms were ciprofloxacin-resistant E. coli (defined as MIC Ͼ4 g/ml) in three (cases 7, 8 and 12) and coagulase-negative staphylococci in one (case No. 6). Standardized disk diffusion antimicrobial susceptibility testing of the three ciprofloxacin-resistant E.coli strains is shown in Table 2 . Only one patient (case No. 6) had documented liver aspergillosis diagnosed on day 35 and one patient (case No. 9) had herpes genitalis diagnosed on day 3. Two patients (case 7 and 12) died before myeloid engraftment due to septic shock caused by ciprofloxacinresistant E. coli bacteremia. No other transplant-related mortalities occurred. The date of the first episode of bacteremia, date of myeloid engraftment and the outcome for each patient are also summarized in Table 1 .
Discussion
An effective prophylactic antibiotic appears able to prevent bacterial infections in BMT recipients. Ciprofloxacin, one of the most promising agents in this regard, has been proven to be very effective in eliminating gram-negative bacteremias (Table 3 ). The dosage of ciprofloxacin in these studies ranged from 500 mg to 1500 mg per day. In our study, we chose the lower dose of 250 mg twice daily, since it has been shown to have equal decontaminating capacity against gram-negative fecal organisms 17 and may also maintain the anaerobic gut flora. The major concern regarding antibiotic prophylaxis is the emergence of drug resistance among microorganisms. Cancer patients receiving fluoroquinolone prophylaxis rapidly become colonized with fluoroquinolone-resistant E. coli 8 and coagulase-negative staphylococci. 18 Over the past few years, reports have been emerging from Europe concerning fluoroquinolone-resistant E. coli bacteremias in neutropenic cancer patients receiving prophylactic fluoroquinolone. 19, 20 In trials organized by the International Antimicrobial Therapy Cooperative Group of EORTC, all 92 strains of E. coli bacteremias isolated during the period from 1983 to 1990 were sensitive to fluoroquinolone. However, 11 of 40 isolates between 1991 and 1993 were highly resistant. 7 Although fluoroquinolone-resistant E. coli bacteremia in BMT recipi- 
An = amikin; Am = ampicillin; Cz = cefazolin; Ctx = cefotaxime; Cfp = cefoperazone; Cro = ceftriaxone; Caz = ceftazidime; C = chloramphenicol; Gm = gentamicin; Pip = pipracillin; Sxt = co-trimoxazole; S = sensitive; R = resistant. ents receiving prophylactic fluoroquinolone seems not to be a serious problem even in the most recent reports, [14] [15] [16] we believe it will be encountered eventually and we report our experience here.
Ciprofloxacin was not introduced to the Veterans General Hospital-Kaohsiung until 1994 and it could be prescribed only after verification of an infectious disease by a specialist. Prophylactic ciprofloxacin was used only in allogeneic BMT and PBSCT recipients after 1997. Between 1997 and 1998, 90% of all E. coli isolates at this hospital were sensitive to ciprofloxacin. Twelve consecutive patients undergoing allogeneic BMT and PBSCT in this period were treated with ciprofloxacin and other antibiotic prophylaxis as described earlier. However, four patients developed bacteremia before myeloid engraftment, with three (cases 7, 8 and 12) having ciprofloxacin-resistant E. coli bacteremias and one (case No. 6) having coagulasenegative staphylococci bacteremia. The dates of transplantation of the three who had ciprofloxacin-resistant E. coli bacteremia were months apart and the antibiotic sensitivity profile of the three isolates was also different. These resistant strains were therefore likely to have emerged independently. The time interval between initiating ciprofloxacin prophylaxis and the development of ciprofloxacin-resistant E. coli bacteremia was 10 days in case No. 7, 14 days in case No. 8, and only 4 days in case No. 12. In addition to case No. 8, who had previously received empirical ciprofloxacin for leukopenic fever during induction chemotherapy, neither case Nos 7 or 12 had been exposed to ciprofloxacin or other fluoroquinolone. Case No. 8 had been admitted to our hospital three times before BMT, case Nos 7 and 12 had not been hospitalized prior to BMT. Case No. 7 had visited our hematology clinic and emergency room about 50 times over a period of 2 years. Case No. 12 had visited the hematology clinic only three times within 1 month of BMT.
The emergence of ciprofloxacin-resistant E. coli bacteremia in our BMT recipients is worth discussing. The most important risk factor for getting a fluoroquinolone-resistant E. coli infection or bacteremia is prior exposure to fluoroquinolone. [20] [21] [22] [23] [24] [25] In our study, however, only one of the three patients with ciprofloxacin-resistant E. coli bacteremia had had prior exposure to fluoroquinolone. Similar conditions have also been reported by Carratalá et al 8 from Spain. According to their data, to be a neutropenic cancer patient receiving fluoroquinolone prophylaxis was the only risk factor for developing fluoroquinolone-resistant E. coli bacteremia and prior quinolone therapy was not a significant factor. The result of our study as well as Carratalá's suggest that fluoroquinolone prophylaxis might actually act as a selection bias for fluoroquinolone-resistant E. coli mutants which were already colonizing the gastrointestinal tract.
Fluoroquinolone-resistant E. coli bacteremia could therefore develop within a very few days after fluoroquinolone prophylaxis. The fluoroquinolone-resistant E. coli may come from the hospital, and probably more important, the community. Spain is known for its increasing incidence of ciprofloxacin-resistant E. coli bacteremias due to the wide prescription of this drug. 26, 27 Ciprofloxacin was also widely prescribed in Taiwan and resistance was thus developed rapidly. In a medical center in northern Taiwan, ciprofloxacin-resistant E. coli was isolated from 18% in 1996 to 48% in 1997 (Meeting Report: Symposium on Current Status of Drug Resistance of Common Pathogens in Taiwan; Taipei, Taiwan, Oct. 4, 1998).
In the face of ciprofloxacin resistance, we cannot propose a more promising agent at present. Many newer fluoroquinolones such as levofloxacin, lomefloxacin, sparfloxacin and trovafloxacin share cross-resistance with ciprofloxacin. 28 Many newer third generation oral cephalosporins lack activity against pseudomonas, which will be problematic. However, Du-6859a (sitafloxacin), a new potent fluoroquinolone, has been reported to retain activity against 80% of isolates resistant to ciprofloxacin 29 and has a good intestinal decontamination effect and low toxicity. 30 Clinical investigation of Du-6859a prophylaxis in BMT will probably be encouraging. Nevertheless, before Du-6859a or some other drug is approved and available for antibiotic prophylaxis in BMT, it is likely that with further use of ciprofloxacin, our experience will be repeated at other institutions. In our patients, the incidence of E. coli bacteremia (25%) while using ciprofloxacin prophylaxis was similar to that seen in patients not receiving preventive therapy or who are receiving trimethoprim-sulfamethoxazole therapy (10-25%). 31 We conclude that the prophylactic efficacy of ciprofloxacin in BMT recipients should be reassessed, especially in areas where the prevalence of fluoroquinolone-resistant strains is high.
